These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505 [TBL] [Abstract][Full Text] [Related]
3. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW; JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Barry M; Mulcahy F; Merry C; Gibbons S; Back D Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951 [TBL] [Abstract][Full Text] [Related]
6. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864 [TBL] [Abstract][Full Text] [Related]
7. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Moyle G Drugs; 2001; 61(1):19-26. PubMed ID: 11217868 [TBL] [Abstract][Full Text] [Related]
9. Delavirdine: a review of its use in HIV infection. Scott LJ; Perry CM Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019 [TBL] [Abstract][Full Text] [Related]
10. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA; N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. Tashima K; Staszewski S; Nelson M; Rachlis A; Skiest D; Stryker R; Bessen L; Overfield S; Ruiz N; Wirtz V AIDS; 2008 Jan; 22(2):275-9. PubMed ID: 18097230 [TBL] [Abstract][Full Text] [Related]
12. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM; Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269 [TBL] [Abstract][Full Text] [Related]
13. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076 [TBL] [Abstract][Full Text] [Related]
14. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination. James JS AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599 [TBL] [Abstract][Full Text] [Related]
15. Clinical history of efavirenz. Ruiz N Int J Clin Pract Suppl; 1999 Jun; 103():3-7. PubMed ID: 10622035 [TBL] [Abstract][Full Text] [Related]
17. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886 [TBL] [Abstract][Full Text] [Related]
18. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]. van Leth F; Lange JM Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943 [TBL] [Abstract][Full Text] [Related]
19. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471 [TBL] [Abstract][Full Text] [Related]
20. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]